Revive Therapeutics Ltd. (RVVTF)
| Previous Close | 0.2950 |
| Open | 0.3090 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2855 - 0.3210 |
| 52 Week Range | 0.1200 - 0.5100 |
| Volume | |
| Avg. Volume | 598,587 |
| Market Cap | 94.964M |
| Beta (5Y Monthly) | 0.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0550 |
| Earnings Date | Feb 28, 2022 - Mar 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Revive Therapeutics Ltd
Provides an update on the Company’s U.S. Food & Drug Administration Phase 3 clinical trial to evaluate ...
- GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The Company submitted request to the FDA to determine potential new clinical endpoints for FDA consideration for EUATORONTO, May 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “
- GlobeNewswire
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business Highlights and Update
Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion product, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for KETARX™ (ketamine injection and infusion product) for anesthesia and procedural sedation TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM)
